Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and target prices for Artiva Biotherapeutics and GeoVax Labs, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 534.15%. GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 72,715.53%. Given GeoVax Labs’ higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Artiva Biotherapeutics.
Valuation & Earnings
This table compares Artiva Biotherapeutics and GeoVax Labs”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | 1,202.69 | -$83.86 million | ($3.30) | -1.86 |
| GeoVax Labs | $2.49 million | 0.61 | -$21.47 million | ($11.34) | -0.02 |
GeoVax Labs has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Artiva Biotherapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.69, meaning that its share price is 269% more volatile than the S&P 500.
Profitability
This table compares Artiva Biotherapeutics and GeoVax Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
| GeoVax Labs | N/A | -743.64% | -394.74% |
Institutional and Insider Ownership
6.1% of GeoVax Labs shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Artiva Biotherapeutics beats GeoVax Labs on 8 of the 14 factors compared between the two stocks.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
